By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Celera today reported that its fourth-quarter sales fell 11 percent as its licensing revenues declined sharply year over year.

The Alameda, Calif.-based molecular diagnostics firm, which announced separately that it will be acquired by Quest Diagnostics for $671 million, brought in total revenues of $34.9 million for the three-month period ended Dec. 25, compared to $39.2 million for Q4 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.